Waldencast plc provided a business update for the first half of 2025, announcing that its Board of Directors has initiated a review of a broad range of strategic alternatives aimed at maximizing shareholder value. Lazard has been retained as the financial advisor for this strategic review. The company stated it does not intend to comment further on the status or timing of this process unless a definitive course of action is approved or other disclosure is deemed appropriate.
Concurrently, Waldencast updated its full-year 2025 outlook, now expecting net revenue growth in the low to mid-single digits, a revision from the previously anticipated mid-teens growth. Adjusted EBITDA margins are now projected to be in the low to mid-teens, down from the prior mid-to-high teens expectation. This revised guidance reflects first-half performance and a more moderated industry environment, alongside purposeful investments for future growth.
The company also announced the postponement of its H1 2025 earnings release and conference call. This delay is due to an expanded evaluation of operating performance, strategic choices, long-term priorities, and goodwill valuation, undertaken in preparation for the strategic review and in light of the recent Novaestiq acquisition. Waldencast is working to finalize this review and file the H1 2025 financials within regulatory deadlines.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.